Operating Profit Margin since 2005
Difficulty: Beginner
Calculation
Allergan PLC, operating profit margin, long-term trends, calculation
| Operating Profit Margin | = | 100 | × | Operating income (loss)1 | ÷ | Net revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | 13.27% | = | 100 | × | 218,512 | ÷ | 1,646,203 |
| Dec 31, 2006 | -21.33% | = | 100 | × | (422,096) | ÷ | 1,979,244 |
| Dec 31, 2007 | 10.24% | = | 100 | × | 255,660 | ÷ | 2,496,651 |
| Dec 31, 2008 | 14.12% | = | 100 | × | 358,128 | ÷ | 2,535,501 |
| Dec 31, 2009 | 13.75% | = | 100 | × | 383,900 | ÷ | 2,793,000 |
| Dec 31, 2010 | 8.56% | = | 100 | × | 305,400 | ÷ | 3,566,900 |
| Dec 31, 2011 | 11.70% | = | 100 | × | 536,200 | ÷ | 4,584,400 |
| Dec 31, 2012 | 5.42% | = | 100 | × | 320,800 | ÷ | 5,914,900 |
| Dec 31, 2013 | -4.88% | = | 100 | × | (423,200) | ÷ | 8,677,600 |
| Dec 31, 2014 | -9.71% | = | 100 | × | (1,267,700) | ÷ | 13,062,300 |
| Dec 31, 2015 | -20.00% | = | 100 | × | (3,014,500) | ÷ | 15,071,000 |
| Dec 31, 2016 | -12.53% | = | 100 | × | (1,825,500) | ÷ | 14,570,600 |
| Dec 31, 2017 | -37.15% | = | 100 | × | (5,921,200) | ÷ | 15,940,700 |
1 USD $ in thousands
Source: Based on data from Allergan PLC Annual Reports
Comparison to Competitors
Allergan PLC, operating profit margin, long-term trends, comparison to competitors
| Allergan PLC | Abbott Laboratories | AbbVie Inc. | Amgen Inc. | Biogen Inc. | Celgene Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2005 | 13.27% | 19.53% | –% | 40.33% | 9.74% | 18.76% | 61.41% | -187.97% |
| Dec 31, 2006 | -21.33% | 9.09% | –% | 27.71% | 16.40% | 21.52% | -29.32% | -169.68% |
| Dec 31, 2007 | 10.24% | 17.67% | –% | 27.81% | 24.59% | 32.69% | 57.98% | -91.55% |
| Dec 31, 2008 | 14.12% | 19.28% | –% | 35.50% | 29.62% | -68.50% | 52.68% | -37.67% |
| Dec 31, 2009 | 13.75% | 20.27% | –% | 38.37% | 29.59% | 32.78% | 54.55% | -19.54% |
| Dec 31, 2010 | 8.56% | 17.31% | –% | 37.82% | 26.48% | 28.21% | 53.62% | -21.23% |
| Dec 31, 2011 | 11.70% | 14.81% | –% | 28.19% | 34.16% | 30.70% | 46.77% | -46.02% |
| Dec 31, 2012 | 5.42% | 20.28% | 31.65% | 33.52% | 33.64% | 32.43% | 42.67% | 33.20% |
| Dec 31, 2013 | -4.88% | 12.03% | 30.14% | 32.25% | 36.29% | 28.43% | 41.87% | 36.11% |
| Dec 31, 2014 | -9.71% | 12.84% | 17.09% | 32.03% | 40.94% | 33.30% | 62.37% | 29.74% |
| Dec 31, 2015 | -20.00% | 14.05% | 32.97% | 40.44% | 45.44% | 24.61% | 69.03% | 30.51% |
| Dec 31, 2016 | -12.53% | 15.27% | 36.60% | 44.74% | 44.99% | 28.31% | 58.87% | 27.38% |
| Dec 31, 2017 | -37.15% | 6.30% | 33.99% | 45.76% | 43.54% | 36.28% | 55.04% | 35.41% |
Source: Based on data from Allergan PLC Annual Reports